Background A subgroup of patients with severe asthma have persistent eosinophilic airway inflammation despite treatment with high intensity corticosteroid treatment. One possible explanation for this pattern of disease is involvement of a type 2 innate lymphoid cells (ILC2s) dependant and relatively corticosteroid resistant pathway generating type 2 cytokines such as IL-5 and Il-13. The presence of high numbers of ILC2s in the nasal polyps commonly associated with severe eosinophilic asthma supports this view. We have carried out a cross-sectional study testing the hypothesis that ILC2 counts are increased in peripheral blood of patients with severe eosinophilic asthma.
Methods Blood was taken from 9 controls and 33 patients with asthma, 23 of whom met the 2014 ERS/ATS guideline criteria for severe asthma and had historical evidence of eosinophilic airway inflammation as defined before (Pavord et al. Lancet 2012;380:651–9). ILC2 were measured as lineage- CD45+CD127+CRTH2+ by flow cytometry and numbers presented as total cell counts and% peripheral blood mononuclear cells.
Results ILC2 counts were repeatable within patients (ICC 0.97; n = 6). Mean ± SD ILC2 counts were 566 ± 379, 323 ± 224, 437 ± 628 and 429 ± 421cells/mL (Figure 1A) and 0.034 ± 0.022, 0.02 ± 0.017, 0.020 ± 0.028 and 0.019 ± 0.014% of total lymphocytes (Figure 1B) in normal controls (n = 9), patients with mild to moderate asthma (n = 10), patients with severe asthma at BTS step 4 (n = 12), and patients with severe asthma at BTS step 5 (n = 11) respectively.
Conclusion Type 2 innate lymphoid cells are scarce in peripheral blood but can be measured consistently. We found no evidence of increased counts in peripheral blood from patients with severe eosinophilic asthma.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.